Organic Active Ingredients TRIZ Cases

A quinazoline carboxamide azetidine combination targets PI3K/Akt/mTOR signaling to re-sensitize endocrine-resistant ER+ tumors.

Polymer adjuvants bind unpaired cysteines on tumor cells to localize TLR or STING agonists, reducing systemic inflammation.

A serotonin 3 receptor agonist composition raises cancer pain threshold with morphine-like analgesia while avoiding sedation and opioid-related side effects.

Structural modification of capsaicin yields stable, low-toxicity anti-tumor compounds with broad-spectrum activity across multiple cancer types.

Patient-specific S1P dosing reduces heart rate and conduction adverse events while preserving treatment effect in autoimmune disease.

Structural tuning of thieno- and thiazolo-pyrimidinones improves NOX4 potency, metabolic stability, and isoform selectivity.

A cyclopentylpyrazolamine derivative is tuned to selectively inhibit CDK2/Cyclin A, stalling the S phase and triggering tumor-cell apoptosis.

Citric acid, ethanol, and HFA134a stabilize pressurized tiotropium aerosol delivery while maintaining high fine particle fraction and bioequivalence.

Combining intestinal organoids with a TNFα inhibitor improves IBD symptom relief and helps inhibit intestinal mucosal fibrosis.

Position-specific seed-region modifications in siRNA reduce off-target toxicity while preserving on-target silencing activity.

Modified oligonucleotides lower SNCA mRNA and alpha-synuclein levels to reduce aggregation and neurodegeneration in related diseases.

A five-day siponimod titration before daily immediate-release maintenance reduces bradycardia and AV block risk in autoimmune treatment.

A Paenibacillus-derived exopolysaccharide forms an adhesive gel plug for rapid hemostasis in irregular or diffuse bleeding without long compression.

Antarctic brown algae β-1,3/1,6-glucan improves PD-1 antitumor response while helping reverse thrombocytopenia and leukocytopenia.

Selective EP4 agonist morpholine carboxamides treat GI and pulmonary disease while limiting systemic distribution and cardiovascular side effects.

Flat 300 mg BID delafloxacin avoids unreliable weight-based dosing in obese patients while reducing toxicity and monitoring burden.

COT inhibition offers a pharmacological route for NASH by reducing liver fibrosis and inflammation, with potential ACC inhibitor combination.

Polyalkylene oxide particle sizing controls osmotic pump dissolution start time without changing drug composition or adding coating steps.

Aromatic-cationic peptides target biotin to mitochondria, improving ATP-related cellular function without the high doses that disrupt cells.

Intramolecular tricyclic benzotriazole derivatives inhibit Keap1, activate Nrf2, and broaden treatment potential for oxidative stress diseases.

Selinexor co-crystals with succinic acid or vanillin improve solubility and stability through controlled crystallization into anhydrous forms.

In vivo encoded synthetic antibodies target Pseudomonas antigens to reduce biofilms and cut repeated dosing and purified antibody cost.

Aminopyrazole CHK1/2 inhibitors boost DNA damage and apoptosis in neuroblastoma and soft tissue sarcoma while limiting CDK1 off-target effects.

Chemotherapy agents activate therapeutic cells or conditioned media to improve tissue repair while avoiding genetic modification and growth factor toxicity.

Propylene glycol or polyethylene glycol keeps melflufen stable, avoids hazardous solvents, and limits degradation during storage.

A potent JAK1/JAK2 inhibitor compound improves treatment of inflammatory and cartilage-related disease while reducing dose and dosing frequency.

Ion-exchanged albumin removes transfection-inhibiting serum components, helping synthetic RNA enter cells with lower toxicity and mutation risk.

By inhibiting myosin-actin crossbridge formation, these quinazolinone dione compounds relieve HCM obstruction and reduce surgical burden.

By binding the TNF-alpha homodimer cavity, TIM-series molecules block homotrimer formation to deliver oral anti-inflammatory activity with lower toxicity.

Small-molecule remdesivir-related compounds offer a treatment route for pulmonary coronavirus infections when masks, distancing, or vaccines are insufficient.

Targeting ME1 addresses metabolic reprogramming in pulmonary hypertension, reducing vascular remodeling, RVSP, and right ventricular hypertrophy.

A high-concentration pregabalin liquid uses pH control for stability, palatability, and rapid relief of feline travel and vet-visit anxiety.

Antisense oligomers alter CNOT3 pre-mRNA splicing to raise PRPF31 levels and help prevent retinal degeneration in retinitis pigmentosa.

A combined miRNA, antithrombin, and electrolyte formulation uses nanoparticle delivery to target fibrosis, arrhythmia, and coagulopathy in cardiac arrest.

KCC2-targeting fused amino pyrimidines aim to improve variable psychosis outcomes by enhancing Cl− transport and restoring GABAergic function.

An ionic neutral lipid reduces phosphatidylcholine bilayer stabilization, enabling endosomal phase transition and better cellular uptake.

A flowable hydrophobically modified chitosan forms a stable tissue barrier that resists blood and exudate while degrading over about two weeks.

A triazole-linked GalNAc conjugate improves liver-targeted oligonucleotide delivery by enabling modular click-chemistry construction and ASGPR binding.

MTA-dependent PRMT5 inhibition targets MTAP-silenced tumors more selectively, improving anti-proliferative activity while limiting off-target toxicity.

ABCG2 inhibition shifts PPIX retention and distribution to improve porphyria therapy, fluorescence imaging, and photodynamic response.

Bicyclic urea compounds target the JAK2 V617F mutant through selective inhibition, helping preserve essential wild-type JAK2 functions.

Formula (I) TNF-alpha inhibitors use targeted structural variation to improve efficacy in inflammatory and autoimmune disease treatment.

Sprinkle capsules and liquid Ibrutinib suspensions improve oral delivery for B-cell cancers in patients with swallowing difficulties.

Lipophilic nucleotide modification enables carrier-free siRNA delivery to extrahepatic tissues while preserving in vivo stability and gene knockdown.

Repeated ultrasound pulses at multiple tissue sites improve nucleic acid delivery and gene expression while limiting cell damage and inflammation.

Selective 5-HT2C agonist dosing reduces seizure frequency and severity while avoiding the cardiac risks linked to less selective 5-HT2 drugs.

A dual solubilized-and-suspended API film boosts oral loading and bioavailability while preserving flexibility and easy administration.

miR-145 suppresses XPC, XPA, and RPA3 to lower NER in chemoresistant breast cancer and restore chemotherapy sensitivity.

Truncated midkine proteins delivered by lipid nanoparticles inhibit midkine activity, cell migration, and cancer cell survival.

An in situ PEG-peptide matrix conforms to irregular wounds, avoids photoinitiators, and degrades into healing-friendly byproducts.